Progranulin and CTRP3 in Metabolic Syndrome

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01668888

Enrollment

127

Registered

2012-08-20

Start date

2012-05-31

Completion date

2012-08-31

Last updated

2012-08-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Metabolic Syndrome

Brief summary

Inflammation has been known to be a pivotal pathogenic mechanism of obesity-related disorders such as type 2 diabetes, metabolic syndrome and atherosclerosis. Adipose tissue functions as a major endocrine organ by adipokine mediated modulation of a number of signaling cascades in target tissues, that has pro-inflammatory or anti-inflammatory activities. Progranulin and CTRP3 are recently discovered novel adipokines. Therefore, the investigators tried to clarify the clinical meaning of these two adipokines in the subjects with or without metabolic syndrome

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

CROSS_SECTIONAL

Eligibility

Sex/Gender

ALL

Age

20 Years to 80 Years

Healthy volunteers

Yes

Inclusion criteria

* 20\<age\<80 * apparently healthy subjects

Exclusion criteria

* a history of CVD * diabetes * stage 2 hypertension * malignancy * severe renal or hepatic disease

Design outcomes

Primary

Measure	Time frame
Serum concentration of progranulin in the subjects with metabolic syndrome	12week
Serum concentration of CTRP3 in the subjects with metabolic syndrome	12week

Secondary

Measure	Time frame
The relationship of serum CTRP3 levels with cardiovascular risk factors	12 week
The relationship of serum progranulin levels with cardiovascular risk factors	12 week

Countries

South Korea

Outcome results